Key Drivers
- Liquidity Strength
- Margin Expansion
- Cash Flow Quality
AIAI Summary
AUPH now looks more like a cash-generating specialty pharma name than a speculative rebound, with strong margins, solid liquidity, and improving LUPKYNIS fundamentals, but the investment case is still highly concentrated in one asset and the stock's weak price action suggests the market wants more proof before re-rating it higher.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Margin Expansion
- •Cash Flow Quality
AUPH has a strong balance sheet and solid cash generation with improving margins and low leverage, but its valuation looks mixed and prior-year earnings were distorted by a tax benefit, so the business remains good operationally yet not clearly cheap.
Price Behavior
Key Price Behavior Insights:
- •Failed rally
- •Support holding
- •Downward momentum
AUPH is weak near term, having failed to hold its late-June rally, now trading below the last month average and needing to reclaim $16.0–$16.4 then $17.2+ to improve while $15.6 support remains key.
ക
Sharp drop from $18.62 on 2026-06-24 to $15.61 on 2026-07-02
Sentiment & News
Key News Insights:
- •Insider buying
- •Volume breakout
- •Analyst upgrade
Aurinia Pharmaceuticals is seeing improving sentiment driven by a large CEO insider buy, a strong stock move on heavy volume, and a recent Strong Buy upgrade.
The news flow is bullish for AUPH and may support near-term momentum if the improving earnings outlook holds
Similar Companies in Healthcare
Other companies in the same sector with AI ratings